Advertisement

European Journal of Pediatrics

, 168:203 | Cite as

Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity

  • S. Bolton
  • B. Cleary
  • J. Walsh
  • E. Dempsey
  • M. J. TurnerEmail author
Original Paper

Abstract

This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy. All women with polycystic ovary syndrome (PCOS) treated with metformin in the first trimester and who delivered a baby weighing 500 g or more between 2003 and 2005 were studied. Subjects were matched for age and parity with randomly selected controls. The perinatal outcomes studied were: growth parameters, gestational age, congenital defects, hypoglycaemia and neonatal unit admission. Sixty-six pregnancies were compared with 66 controls; all had singleton deliveries. There was no difference in mean birth weight between the metformin and the control groups (p = 0.84). The percentage of small (<10th centile) and large (>90th centile) for gestational age babies was lower in the metformin group. In the metformin group, there were no major congenital malformations and 24% of the babies were admitted to the neonatal intensive care unit (NICU) compared with 27% of the babies in the control group (non-significant). Neonatal hypoglycaemia was less common in the metformin group (18.5% vs. 24.5%) and fewer babies required intravenous glucose therapy (6.3% vs. 12%). We found no evidence that the continuation of metformin in the first trimester of pregnancy was associated withan adverse foetal outcome.

Keywords

Metformin Polycystic ovarian syndrome Neonatal outcome 

Notes

Acknowledgements

Contribution of authors:

Suzanne Bolton: manuscript production, data collection and analysis

Brian Cleary, Jennifer Walsh: data collection and analysis

Eugene Dempsey, Michael Turner: contributed to manuscript preparation

Suzanne Bolton is a Specialist Registrar in Paediatrics.

There is no conflict of interest in this research. No funding was received.

References

  1. 1.
    Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS (2006) A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12:673–683PubMedCrossRefGoogle Scholar
  2. 2.
    Gairdner D, Pearson J (1971) A growth chart for premature and other infants. Arch Dis Child 46:783–787PubMedCrossRefGoogle Scholar
  3. 3.
    Gilbert C, Valois M, Koren G (2006) Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 86:658–663PubMedCrossRefGoogle Scholar
  4. 4.
    Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46–52PubMedCrossRefGoogle Scholar
  5. 5.
    Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A (2004) Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19:510–521PubMedCrossRefGoogle Scholar
  6. 6.
    Harborne L, Fleming R, Lyall H, Norman J, Sattar N (2003) Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361:1894–1901PubMedCrossRefGoogle Scholar
  7. 7.
    Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87:524–529PubMedCrossRefGoogle Scholar
  8. 8.
    Kovo M, Weissman A, Gur D, Levran D, Rotmensch S, Glezerman M (2006) Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med 19:415–419PubMedCrossRefGoogle Scholar
  9. 9.
    Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, Schlaff W, Coutifaris C, McGovern PG, Cataldo NA, Steinkampf MP, Nestler JE, Gosman G, Guidice LC, Leppert PC; Reproductive Medicine Network (2006) The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril 86:914–933PubMedCrossRefGoogle Scholar
  10. 10.
    Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MD, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551–566PubMedCrossRefGoogle Scholar
  11. 11.
    Lord JM, Flight IHK, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951–953PubMedCrossRefGoogle Scholar
  12. 12.
    McCarthy EA, Walker SP, McLachlan K, Boyle J, Permezel M (2004) Metformin in obstetric and gynecologic practice: a review. Obstet Gynecol Surv 59:118–127PubMedCrossRefGoogle Scholar
  13. 13.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25Google Scholar
  14. 14.
    Thatcher SS, Jackson EM (2006) Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 85:1002–1009PubMedCrossRefGoogle Scholar
  15. 15.
    Turner MJ, Langan H, Farah N, Byrne K, Cleary B (2005) Metformin: an advance in ovulation induction. Ir Med J 98:133–134PubMedGoogle Scholar
  16. 16.
    Turner MJ, Walsh J, Byrne KM, Murphy C, Langan H, Farah N (2006) Outcome of clinical pregnancies after ovulation induction using metformin. J Obstet Gynaecol 26:233–235PubMedCrossRefGoogle Scholar
  17. 17.
    Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM (2004) Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 19(8):1734–1740PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • S. Bolton
    • 1
  • B. Cleary
    • 1
  • J. Walsh
    • 1
  • E. Dempsey
    • 1
  • M. J. Turner
    • 1
    Email author
  1. 1.UCD School of Medicine and Medical ScienceCoombe Women’s HospitalDublin 8Ireland

Personalised recommendations